Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Evommune, Inc. (NYSE: EVMN) (Evommune or the Company), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced...